Related Experiment Video
Updated: Jul 9, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Mild cognitive impairment (MCI): a historical perspective
Barry Reisberg1, Steven H Ferris, Alan Kluger
1Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA. barry.reisberg@med.nyu.edu
Abstract:
Descriptions of dementia can be traced to antiquity. Prichard (1837) described four dementia stages and Kral (1962) described a "benign senescent forgetfulness" condition. The American Psychiatric Association's DSM-III (1980) identified an early dementia stage. In 1982, the Clinical Dementia Rating (CDR) and the Global Deterioration Scale (GDS) were published, which identified dementia antecedents. The CDR 0.5 "questionable dementia" stage encompasses both mild dementia and earlier antecedents. GDS stage 3 described a predementia condition termed "mild cognitive decline" or, alternatively, beginning in 1988, "mild cognitive impairment" (MCI). This GDS stage 3 MCI condition is differentiated from both a preceding GDS stage 2, "subjective cognitive impairment" (SCI) stage and a subsequent GDS 4 stage of mild dementia.GDS stage 3 MCI has been well characterized. For example, specific clinical concomitants, mental status and psychological assessment score ranges, behavioral and emotional changes, neuroimaging concomitants, neurological reflex changes, electrophysiological changes, motor and coordination changes, and changes in activities, accompanying GDS stage 3 MCI have been described.Petersen and associates proposed a definition of MCI in 2001 which has been widely used (hereafter referred to as "Petersen's MCI"). Important differences between GDS stage 3 MCI and Petersen's MCI are that, because of denial, GDS stage 3 MCI does not require memory complaints. Also, GDS stage 3 MCI recognizes the occurrence of executive level functional deficits, which Petersen's MCI did not. Nevertheless, longitudinal and other studies indicate essential compatibility between GDS stage 3 MCI and Petersen's MCI duration and outcomes.
Insights
The Global Deterioration Scale (GDS) stage 3 describes mild cognitive impairment (MCI) as a predementia stage. This stage is distinct from subjective cognitive impairment and mild dementia, with established characteristics and outcomes.
Area of Science:
- Neurology
- Gerontology
- Psychiatry
Background:
- Historical descriptions of dementia date back to antiquity.
- Early diagnostic scales like the Clinical Dementia Rating (CDR) and Global Deterioration Scale (GDS) were developed to identify dementia and its antecedents.
- The GDS stage 3, termed mild cognitive impairment (MCI), represents a predementia condition.
Observation:
- GDS stage 3 MCI is characterized by specific clinical, cognitive, behavioral, and neuroimaging findings.
- It is differentiated from subjective cognitive impairment (GDS stage 2) and mild dementia (GDS stage 4).
- While Petersen's MCI (2001) is widely used, GDS stage 3 MCI includes executive deficits and does not require memory complaints due to potential denial.
Findings:
- GDS stage 3 MCI is a well-characterized predementia stage.
- Longitudinal studies show compatibility in duration and outcomes between GDS stage 3 MCI and Petersen's MCI.
- Key differences include the absence of mandatory memory complaints in GDS stage 3 MCI and its recognition of executive functional deficits.
Implications:
- Understanding GDS stage 3 MCI aids in early identification and potential intervention for cognitive decline.
- The characterization of GDS stage 3 MCI provides a framework for clinical assessment and research.
- Compatibility with Petersen's MCI suggests a consistent understanding of MCI progression and prognosis across different diagnostic criteria.
More Related Videos
Related Concept Videos
Dementia l: Introduction
Intellectual Disability
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Development During Adulthood
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

